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chronic pyelonephritis was made. She was treated with antibiot-
ics, blood transfusions, and twice-weekly hemodialysis via a
left Brescia fistula. Further medical details are not available
from her Pakistani records.
She came to the United Kingdom nine years ago, some six
months following her initial presentation. When first seen at
the Royal Manchester Children’s Hospital, physical examina-
tion was essentially unchanged. Her height was 143.5 cm (25th
centile) and weight 27.6 kg (3rd centile). She was anemic but
there were no other significant findings. Laboratory investiga-
tions revealed: hemoglobin, 65 g/liter; white blood cell count,
8.5 3 109/liter; platelets, 228 3 109/liter; sodium, 136 mmol/
liter; potassium, 5.2 mmol/liter; calcium, 1.72 mmol/liter; phos-
phate, 1.9 mmol/liter; albumin, 37 g/liter; urea, 34.8 mmol/liter
(97.5 mg/dl); and serum creatinine, 1037 mmol/liter (11.7 mg/
dl). She was HBsAg and HBeAg positive and HBeAb negative.CASE PRESENTATION
She was treated for renal osteodystrophy with 1a-hydroxy-
An 11-year-old girl presented to her local nephrology service cholecalciferol and was transferred to North Manchester Gen-
in Pakistan with a five-month history of fever, bilateral loin eral Hospital for hemodialysis at the infectious diseases center
pain, and progressive weight loss. Over the preceding one to because of her hepatitis B positivity. Shortly after starting he-
two months, she had also developed dysuria and intermittent modialysis, significant problems with vascular access resulted
vomiting. in her renal replacement treatment being changed to chronic
She was born by normal vaginal delivery at term and there ambulatory peritoneal dialysis (CAPD), and she was trans-
were no perinatal problems. At three years of age, she was ferred back to the care of the Royal Manchester Children’s
said to have passed a calculus, but no investigations were per- Hospital. She remained well dialyzed and responded well to
formed at that time. Her only other significant past history was erythropoietin therapy. Following her conversion to CAPD
a single febrile illness associated with vomiting at four years she spontaneously seroconverted to hepatitis B and cleared
of age, when a presumptive diagnosis of urinary tract infection her viral load.
was made. Unfortunately, no urine was sent for culture, al- The other medical problem at that time was her renal osteo-
though she was treated with antibiotics and made a full re- dystrophy. Despite aggressive medical management and an
covery. apparent biochemical response to treatment (calcium and
Her parents, who were first cousins, both were in good phosphate were both within the normal range, and her PTH
health, as were her four sisters and one brother. There was was at the lower level of normal), she continued to be troubled
some uncertainty as to whether she and her siblings were from by bone and joint pain. This eventually culminated in an undis-
the same marriage. placed subcapital fracture of the left hip and bilateral stress
Physical examination revealed a small and clinically anemic fractures of both lower femurs. These were managed conserva-
girl. Laboratory investigation disclosed: BUN, 42.1 mmol/liter tively by the orthopedic surgeons at the time but unfortunately
(118 mg/dl); creatinine, 734 mmol/liter (8.3 mg/dl); calcium, resulted in valgus deformities and flexion contractures of both
1.75 mmol/liter (7.0 mg/dl); and hemoglobin, 61 g/liter. A renal knees. Because of these ongoing bone problems, a bone biopsy
ultrasound study revealed a 4 mm echogenic stone in the right was performed to clarify the precise abnormality underlying
kidney, a 15 mm and a 10 mm stone in the left kidney, no these problems.
hydronephrosis, and bilateral small kidneys. The bone biopsy demonstrated the presence of osteomalacia
A diagnosis of end-stage chronic renal failure secondary to with large quantities of crystals and a probable diagnosis of
primary hyperoxaluria. Liver biopsy, urine, CAPD fluid, and
plasma samples were sent for diagnostic confirmation. Mea-
surement of alanine:glyoxylate aminotransferase (AGT) cata-The Nephrology Forum is funded in part by grants from Hoechst
lytic activity in the liver biopsy sample disclosed 0.09 mmolMarion Roussel, Incorporated; Amgen, Incorporated; Merck & Co.,
Incorporated; Dialysis Clinic, Incorporated; and R & D Laboratories. substrate transformed/hr/mg protein (reference range, 2.75 to
8.38 mmol/hr/mg protein). An SDS-PAGE immunoblot test in
Key words: urolithiasis, nephrocalcinosis, liver-kidney transplantation, the liver biopsy sample revealed no AGT immunoreactivity.
pyridoxine, oxalate stones. Analysis of the urine revealed: serum creatinine, 3.42 mmol/
liter; oxalate, 0.67 mmol/liter; and glycolate, 0.40 mmol/liter. 1999 by the International Society of Nephrology
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Analysis of the CAPD fluid disclosed: creatinine, 478 mmol/ ment has not been attempted because of the likelihood of
further poor healing secondary to her metabolic bone disease,liter, and oxalate, 36 mmol/liter. The plasma contained 699
mmol/liter of creatinine and 77.8 mmol/liter of oxalate. which itself continues to cause bone and joint pain. All these
factors in combination have resulted in her now being unableThe results of the assay procedures in the liver biopsy sample
are compatible with a diagnosis of the more common variant to walk and thus wheelchair-bound. In addition, she has devel-
oped chronic osteomyelitis of her left ankle, probably second-of primary hyperoxaluria, type 1, with reduced catalytic activity
of AGT. The oxalate levels in the urine, plasma, and CAPD ary to a dialysis-line infection.
fluid support this diagnosis. Prior to her transplant she had borderline malnutrition; since
In view of this diagnosis and the fact that she was free of her surgery, her nutritional state has deteriorated further. Since
hepatitis, she was accepted onto the transplant waiting list her transplant, she has not maintained an adequate level of
for combined liver and kidney transplantation. She received a nutrition despite adequate dialysis and has been receiving sup-
combined transplant four years ago at age 16 years. The donor plementary nocturnal nasogastric feeding almost continuously
was a 7-year-old male who had died in a traffic accident. Viral over this period. She remains at all times at a barely adequate
serology was positive for cytomegalovirus only. Mismatches level of nutrition.
were A2, B2, and DR1. Technically the procedure was uncom- She also has developed persistent hypotension over the last
plicated, but primary nonfunction of her renal graft necessi- year. Earlier, her blood pressure had been on the order of 130/
tated ongoing hemodialysis. Renal biopsies at days 8, 18, 22, 80 mm Hg. Now her systolic blood pressure rarely exceeds 80
and 40 showed acute tubular necrosis and a few crystals, but mm Hg, despite careful attention to fluid balance. Without a
no evidence of rejection. At day 30 she also developed pelvi- doubt her hypotension has contributed to the difficulties
calyceal dilation secondary to a vesicoureteral junction urinary around forming and sustaining permanent vascular access. The
leak, for which a nephrostomy was inserted. Following re- question has arisen whether this level of blood pressure would
exploration on day 37, the donor ureter was anastomosed to be capable of maintaining a renal transplant. She is currently
her left native ureter over a double-J stent, which was removed being evaluated by cardiologists for this problem. Echocardio-
at day 50. Her maximal urine output was 200 ml/day and she graphy has demonstrated good left-ventricular function with
remained dialysis-dependent throughout. Her poor renal func- no valvular abnormalities. A MUGA scan demonstrated an
tion was attributed to crystal deposition. The liver transplant ejection fraction of 34%. This problem is as yet not resolved.
was a complete success, but despite this and aggressive daily
ultrafiltration/hemodialysis, her oxalate levels remained 10 to
20 times greater than the upper limit of normal.
Since receiving her transplant, she has had a number of
problems. Initially the liver allograft functioned well. Twelve
DISCUSSIONmonths after the transplant, however, her hepatic function
worsened. Laboratory results were: sodium, 137 mmol/liter; Dr. Pierre Cochat (Head, Renal Unit, Hoˆpital Edouard
potassium, 3.4 mmol/liter; urea, 3.4 mmol/liter; creatinine, 113 Herriot; Professor of Pediatrics, Universite´ Claude Ber-
mmol/liter; bilirubin, 36 mmol/liter; ALT, 45 mmol/liter; ALP
nard; and INSERM U499, Lyon, France): Primary hyper-(hepatic isoenzyme), 1464 mmol/liter; and albumin, 28 g/liter.
oxaluria type 1 (PH1, McKusick 259900), the most com-Her cyclosporine A level was 32 ng/ml.
She was asymptomatic throughout, and all investigations mon form of PH (Table 1), is a rare autosomal-recessive
including ultrasound scan and liver biopsy were normal. Endo- disorder characterized by increased urinary excretion of
scopic retrograde cholangiopancreatography failed for techni-
calcium oxalate, recurrent urolithiasis, nephrocalcinosis,cal reasons. Her liver function returned to baseline levels with-
and accumulation of insoluble oxalate throughout theout specific treatment over a number of months and no cause
was ever found for this episode. Since that time she has had body (oxalosis) [1]. The disease is due to a functional
no further problems, although her alkaline phosphatase is per- defect of the liver-specific peroxisomal alanine:glyoxy-
sistently elevated. She is maintained on cyclosporine A (Neo- late aminotransferase (AGT, E.C. 2.6.1.44). The re-
ral) and prednisolone.
sulting decreased transamination of glyoxylate to glycineShe has a number of continuing problems related to her
leads to a subsequent increase in its oxidation to oxalate,renal replacement therapy. She is dialysis-dependent and is
maintained on hemodialysis four hours three times per week; which is a poorly soluble end product (Fig. 1). Human
this dialysis dose appears to be adequate. Unfortunately, since liver AGT cDNA and genomic DNA have been cloned
she lost her first fistula, there has never been successful creation and sequenced; the normal AGT gene (that is, AGXT)of permanent vascular access despite a number of attempts.
maps to chromosome 2q37.3 [2–4].Over the last three years, she has been dialyzed with permanent
Because PH1 is a rare, orphan disease, its diagnosis iscatheters, and she has now exhausted possible access sites for
replacement should it become necessary. The possibility of often delayed and its initial management inappropriate.
retransplantation has been considered, and her father would The medical history of this young woman raises the cru-
be a suitable candidate for a live donor. However, because of cial paradox of successful enzyme replacement and sub-her persistently raised oxalate levels and the probability that
sequent uncertain quality of life following combinedher first transplant was lost through oxalate deposition, retrans-
kidney-liver transplantation. This case illustrates the epi-plantation has not been attempted.
Orthopedic issues remain a major problem. Her flexure con- demiology and natural history of this disease, as I will
tractures have failed to respond to treatment, and she is left discuss in this Nephrology Forum.
with 408 fixed deformities of both knees. The fracture of her The average prevalence rate of PH1 has been esti-right hip failed to unite, and the screw with which it was fixed
mated to be 1.05/106/year and its average incidence rateencroached upon the hip joint, necessitating its removal. The
hip has since then become dislocated. More aggressive treat- 0.12/106/year in France (that is, 1:120,000 live births); it
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Table 1. Classification of primary hyperoxalurias Along with the skeleton, systemic involvement in-
cludes many organs: heart (cardiomyopathy, conductionType 1 Increased urinary excretion of glycolate
Deficiency of alanine:glyoxylate defects), nerves (peripheral neuropathy, mononeuritis
aminotransferase in liver peroxisomes multiplex), joints (synovitis), arteries (disseminated oc-Type 2 Increased urinary excretion of L-glycerate
clusive vascular lesions, limb gangrene, arteriovenousDeficiencies of both D-glycerate dehydrogenase and
glycosylate reductase in hepatocytes and leukocytes fistula thrombosis), skin (ulcerating subcutaneous cal-
Type 3 Non-type-1, non-type-2 primary hyperoxaluria cium oxalate calcinosis, livedo reticularis), soft tissues,Unidentified enzyme defect
and retina [1, 9].
The oxalate burden varies considerably from one indi-
vidual to another, and transplantation ideally should
precede advanced systemic oxalate storage. Criteria foris much more frequent when parental consanguinity is
estimating the prediction of further changes in GFRpresent, as in many pedigrees of Muslim families [1, 5].
and allowing timely assessment of the oxalate burdenAbove all, the approach to diagnosis and management
are needed. It does appear that close monitoring ofof PH1 is determined by the socioeconomic condition
GFR, plasma oxalate-to-plasma creatinine (Pox:Pcr) ratio,of the country of origin (Table 2). As illustrated by the
plasma calcium oxalate saturation, and possibly systemiccase report, the median age at onset of initial symptoms
involvement (as assessed by bone histology, dual-energyis five years, ranging from birth to the sixth decade; end-
x-ray absorptiometry, oxalate metabolic pool size, tissuestage renal disease (ESRD) is reached by the age of 15
oxalate accretion rate), should assist in timing trans-years in one-half of PH1 patients [5]. Primary hyperoxa-
plantation [6, 8, 10].
luria type 1 presents with symptoms referable to the
urinary tract in more than 80% of cases: loin pain, hema- Diagnosis
turia, urinary tract infections, or passage of a stone [5].
Primary hyperoxaluria type 1 can be diagnosed by
Calculi—multiple, bilateral, and radioopaque—are com- measurement of urine oxalate (Uox) and glycolate (Ugl)posed of calcium oxalate and accompanied by monohy- excretion rates and by plasma oxalate measurement (Ta-
drate calcium oxalate crystalluria (whewhellite). Neph- ble 3). Concomitant hyperoxaluria and hyperglycolic aci-
rocalcinosis, best demonstrated by ultrasound, is present duria are indicative of PH1, but some patients with PH1
on plain abdominal radiograph at an advanced stage. do not have hyperglycolic aciduria [4].
Most patients develop ESRD over a short period, and Sample collection and storage conditions are critical to
infants usually have the most rapid course [6]. When the securing meaningful results for diagnosis and treatment.
GFR falls to below 20 to 40 ml/min/1.73 m2, continued Indeed, Pox measurement can be influenced by in-vitro
overproduction of oxalate by the liver along with re- generation of oxalate from ascorbate, blood pH, and
duced oxalate excretion by the kidneys leads to increas- certain drugs; preferred collection methods are oxalate
ing oxalate deposition in many organs [6, 7]. Tissue oxidase-based coupled with a colorimetric detection us-
biopsy analyses, rarely required at present for diagnosis, ing chemiluminescence, ion chromatography, or high-
should be limited to patients whose biochemistry and performance liquid chromatography [11, 12]. Both Uox
enzyme analyses are not available; I will discuss patients and Ugl can be assessed by an oxalate oxidase-based kit,
considering liver transplantation in a moment. Infantile gas chromatography coupled with mass spectrometry, or
oxalosis often presents as a life-threatening disease be- isotope dilution [1, 12].
cause of both oxalate load and immature GFR; death Alanine:glyoxylate aminotransferase (AGT) catalytic
can ensue by the age of one year [1, 4]. On the other activity can be assessed in a freshly frozen liver specimen
hand, some patients are asymptomatic, and PH1 is dis- (2 mg of liver tissue) taken by percutaneous needle
covered by family screening. biopsy. However, glutamate:glyoxylate aminotransfer-
Bone is the major compartment of the insoluble oxa- ase (GGT) also can catalyze alanine:glyoxylate transami-
late pool, and therefore bone disease is the most dis- nation to the level of around 65%; therefore the GGT
abling complication of oxalosis that cannot be prevented assay must be coupled and the appropriate correction
by regular dialysis treatment. Bone oxalate concentra- made for the crossover [15]. Immunoreactive AGT pro-
tion is negligible in normal subjects, whereas it reaches tein can be assessed by immunoblotting and is much
5.1 6 3.6 mmol/g of bony tissue in dialyzed patients more stable than AGT catalytic activity [16]. However,
without PH and 15 to 907 mmol/g in dialyzed patients patients with AGT activity between 15% and 50% can-
with PH [8]. Calcium oxalate crystal deposition is pro- not be distinguished from carriers on the basis of catalytic
gressive and related to time on dialysis. It also affects the activity alone, and the intracellular distribution of immu-
histomorphometric patterns. That is, oxalate deposition noreactive AGT must be documented by immunoelec-
increases resorptive areas and decreases bone formation tron microscopy [4].
In our experience of patients with a presumptive diag-rate [8].
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Fig. 1. Simplified pathways of glyoxylate metabolism. Thick lines indicate the consequences of the metabolic block (X) in PH1 [1]. Abbreviations
are: AGT, alanine:glyoxylate aminotransferase; GGT, glutamate:glyoxylate aminotransferase; GO, glycolate oxidase; GR, glyoxylate reductase;
LDH, lactate dehydrogenase.
nosis of PH (Table 4), 14% were identified as non-PH1
because AGT activity and immunoreactivity were nor-
mal. Although 82% of PH1 patients have undetectable
Table 2. Current worldwide approach of PH1: The paradoxlevels of AGT catalytic activity (enz-), the remainder
have activities in a range of 5% to 50% of the mean Developed Developing
countries countriesnormal activity (enz1); most of enz- (10 of 12) patients
also have no immunoreactive AGT protein (crm-); in Incidence rate Low High (when
consanguinityenz1 patients the level of immunoreactive protein paral-
is present)lels the level of enzyme activity. These data are compara-
Diagnostic procedure
ble to those obtained by Danpure and Rumsby [4]. There Clinical observation 1 11
Family history 1 11is no clear relationship between residual AGT catalytic
Radiology/sonography 1 11activity and clinical severity in PH1.
Kidney/bone biopsy 1 11
In normal human hepatocytes, AGT, exclusively local- Uoxa 11 1
Ugl 1 2ized within the peroxisome, is unable to achieve its meta-
AGT activity 11 2bolic function (that is, glyoxylate detoxification) when
DNA analysis 11 2
located within the mitochondria [1, 17]. In most enz-/ Prenatal diagnosis
Requirement 1 11crm1 PH1 patients, the immunoreactive but catalytically
Availability 11 2defunct AGT is also localized totally within the peroxi-
Treatment
somes; in enz1/crm1 PH1 patients, 90% of the immuno- Conservative 11 1
Dialysis 6 11reactive AGT is localized in the mitochondria and only
Kidney Tx 6 1110% in the peroxisome [4, 18].
Liver-kidney Tx 11 2
Polymorphic variations have been identified in AGXT Withdrawal 2 11
(74 bp duplication within intron 1, Pro11Leu substitu- a Abbreviations are: Uox, urine oxalate; Ugl, urine glycolate; AGT, alanine:gly-
oxylate aminotransferase; Tx, transplantation.tion); such a minor allele is present in 20% of normal
Caucasoids [4]. So far, 15 to 20 mutations in genomic
DNA have been identified and might play a role in
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Table 3. Plasma and urine concentrations of oxalate and glycolate: supported by calcium oxalate crystallization inhibitors,
Normal values [1, 11–14]
that is, sodium (or potassium) citrate, 150 mg/kg per
Urine Uox/24 hr Child ,0.46 mmol/1.73 m2 day [21] or orthophosphate, 30 mg/kg/day [22]. Diuretics
Adult ,0.40 mmol/1.73 m2 require careful management, as furosemide can maintainUox/Ucr ,1 year ,0.25 mmol/mmol
a high urine output but has the risk of increased calciuria,1–4 years ,0.13 mmol/mmol
5–12 years ,0.07 mmol/mmol whereas hydrochlorothiazide is a weaker diuretic but
Adult ,0.08 mmol/mmol is associated with an appreciable decrease in calciumUgl/24 hrs Child ,0.55 mmol/1.73 m2
excretion; a combination of both diuretics would helpAdult ,0.26 mmol/1.73 m2
Ugl/Ucr ,1 year ,0.07 mmol/mmol reduce the urinary calcium concentration.
1–4 years ,0.09 mmol/mmol Pyridoxal-5-phosphate is a cofactor of AGT, so oral5–12 years ,0.05 mmol/mmol
pharmacologic doses (2 to 15 mg/kg/day) have been used,Adult ,0.04 mmol/mmol
producing a significant reduction in oxalate excretion inPlasma Pox Child ,7.4 mmol/liter
a small number of patients [1, 4, 22]. The molecularAdult ,5.4 mmol/liter
Pox/Pcr Child ,0.189 mmol/mmol basis of pyridoxine responsiveness is not known, and the
Adult ,0.055 mmol/mmol efficacy of pyridoxine therefore must be tested for each
Abbreviations are: Uox, urine oxalate; Ucr, urine creatinine; Ugl, urine glycolate; patient at an early stage of the disease [6]. RestrictionPox, plasma oxalate; Pcr, plasma creatinine.
of dietary oxalate intake (strawberries, rhubarb, spinach,
coffee, tea, nuts) has only a minor influence on the dis-
ease. The effect of conservative measures can be assessed
by serial determinations of crystalluria score, calciumenzyme trafficking [4]: for example, Gly170Arg substitu-
tion is found in 30% of PH1 patients and appears to act oxalate supersaturation (Equil2t software), and calcium
oxalate inhibition [22, 23]. More recently, an attempt atwith Pro11Leu polymorphism, leading to peroxisome-to-
mitochondrion AGT mistargeting; and Gly82Glu muta- inhibiting hepatic oxalate synthesis by using (L)-oxothia-
zolidine-4-carboxylate (OTZ) has been reported and istion is associated with normal localization but loss of
catalytic activity. under evaluation [24].
Conventional dialysis is unsuitable for patients whoThe study of DNA among different ethnic groups has
revealed clinically relevant information. The minor allele have reached ESRD [1, 6], because it cannot clear a
sufficient amount of oxalate. As a consequence, the clini-has a frequency of only 2% in Japanese populations [4].
In our experience, the complete deletion of the AGXT cal status at transplantation clearly depends on the time
on dialysis [25]. In adults, the production of oxalate bygene has been found only in a Turkish family; the
Gly82Glu mutation in exon 2 has been found only in the liver ranges from 3500 to 7500 mmol/day, and the
average tissue accretion rate is more than 50 mmol/kg/Pakistanis. Another genetic defect, that is, combined
deletion and insertion in exon 8, has been specifically day [26]. Oxalate elimination in children undergoing reg-
ular hemo- or peritoneal dialysis ranges from 950 to 1400reported in two unrelated patients of Pakistani origin
[19]. mmol/day [27]. To remove sufficient amounts of oxalate,
daily hemodialysis (six to eight hours per session) isWe noted polymorphism in 64% of the patients, and
point mutation has been identified in only 38% (Table therefore required. Such a strategy cannot be routinely
used but it might be helpful before and after isolated4). Prenatal diagnosis from DNA analysis of chorionic
villus (9 to 12 weeks gestation) or amniocytes (16 weeks kidney or combined kidney-liver transplantation [6, 28].
Conventional long-term dialysis is generally regardedgestation) is possible either from mutational analysis us-
ing PCR amplification or from linkage analysis; the latter as contraindicated because it only prolongs a miserable
existence. Instead of dying quickly from uremia, patientstechnique is more generally applicable, provided DNA
from the affected family member and parents is available treated in this way promptly experience a deterioration
in their quality of life; they die miserably after possiblyfor study [4].
years of increasing morbidity because of the progression
Treatment of extrarenal oxalate deposition [9].
Renal transplantation, first performed in 1969 in pa-Unfortunately, conservative treatment was not avail-
able for today’s patient, as in all cases in whom diagnosis tients with primary hyperoxaluria (the pathophysiology
of the disease was not yet identified at that time), allowshas not been made before ESRD is reached. When Uox
concentration exceeds 0.4 mmol/liter, the risk of stone efficient removal of soluble oxalate. However, because
the biochemical defect is in the liver, overproduction offormation is increased, especially if urine calcium ex-
ceeds 4 mmol/liter; therefore supportive therapy should oxalate continues unabated. Although plasma oxalate
levels are lower after renal transplantation than in dia-be adapted to keep the concentrations of oxalate and
calcium below these limits [20]. Low concentrations can lyzed patients, oxalate levels remain elevated, and oxa-
late deposition in tissues, including the graft, continuesbe achieved by a high fluid intake (. 2 liters/m2/day)
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Table 4. AGT catalytic activity (N 5 51) and DNA analysis (N 5 25) in patients presenting with a presumptive diagnosis
of primary hyperoxaluria
AGT catalytic activity ,5% N 5 36 (70%) enz2
5%–50% N 5 8 (16%) enz1
Normal N 5 7 (14%) PH1 excluded
DNA analysis Polymorphisms IVS1 duplication 16 (64%)
Pro11Leu 16 (64%)
Mutations Gly41Arg 0
Gly82Glu 1 (4%)
Phe152Ile 3 (12%)
Gly170Arg 5 (20%)
Complete deletion of the gene 1 (4%)
Abbreviations are: AGT, alanine:glyoxylate aminotransferase; enz2, undetectable AGT catalytic activity; enz1, significant or normal AGT catalytic activity.
plant is performed when there is substantial residual
renal function, that is, a GFR ranging from 20 to 30 ml/
min/1.73 m2, and in the absence of important extrarenal
involvement [6]. Good results have been reported after
early renal transplantation and vigorous perioperative
dialysis [28]. The use of living-related donors should be
avoided because the overall results are poor and not
significantly better than with cadaver donors in PH1 [25,
29, 31].
The 1990s witnessed an attempt at treating PH1 using
liver transplantation. Since the liver is the only organ
responsible for the detoxification of glyoxylate by AGT,
the excessive production of oxalate will continue as long
as the native liver is left in place. Therefore any form
of enzyme replacement therapy is successful only when
the deficient host liver is removed concomitantly [32].
Liver transplantation can be regarded as a biochemical
Fig. 2. Graft survival after isolated renal transplantation. Thin line, cure; it is able to provide an adequate source of a defi-
patients from the PH1 Transplant Registry Report [25]; thick line,
cient protein in a number of inborn errors of metabolismpatients from the EDTA Registry [29].
[33]. The first disorders considered in this respect were
associated with severe hepatic injury, such as type-IA
glycogen storage disease or tyrosinemia. Liver replace-
post transplantation. The high rate of urinary oxalate ment therapy to correct a defect responsible for extrahe-
excretion originates from both new oxalate production patic complications, in the presence of grossly normal
and old oxalate deposits in tissues. hepatic structure and function, was first performed in
The amount of oxalate that accumulates in the grafted homozygous familial hypercholesterolemia. In patients
kidney varies and is not related to the rate of clinical with pyridoxine-resistant PH1, liver transplantation can
recurrence of the disease after renal transplantation. supply the missing enzyme in the correct organ (liver),
Overall organ survival is often short: data from the Euro- cell (hepatocyte), and intracellular compartment (perox-
pean Dialysis and Transplant Association Registry isome) [4, 32]. Before liver transplantation is considered,
showed in 1990 that three years after renal transplanta- a liver biopsy is needed to confirm the suspected AGT
tion, only 23% of living donor and 17% of cadaver donor deficiency. The ultimate goal of organ replacement in
grafts were functioning; 26% of the recipients had died PH1 is to change a positive whole-body accretion rate
after three years (Fig. 2) [29]. The long-term outcome into a negative one by reducing endogenous oxalate syn-
of PH1 after renal transplantation remains uncertain, thesis and providing good oxalate clearance via either
with a 5- to 10-year patient survival rate ranging from the native or the transplanted kidney [34].
10% to 50% [6, 25]. In addition, renal transplantation Metabolic diseases account for 1% to 23% of all indi-
does not necessarily prevent the progression of skeletal cations for liver transplantation, which are mostly per-
and vascular complications [6, 29]. The chances of a formed in the pediatric age group because of the early
successful transplant are unrelated to residual hepatic onset of such diseases; some of these patients require
simultaneous grafts of other organs such as kidney orenzyme activity [30]; success is improved only if the trans-
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damaged in PH1 patients by high amounts of oxalate
released from the body stores, in addition to the usual
causes of graft failure such as rejection, cyclosporine/
tacrolimus toxicity, etc. [39].
Isolated liver transplantation should be the first-choice
treatment in selected patients with PH1 before the onset
of chronic renal failure [34, 40, 41]. Such a strategy is
tempting but raises ethical controversies; to date, around
20 patients have received an isolated liver transplant
without unanimous criteria for such a decision. Selection
of patients and timing of the procedure remain question-
able.
Deposits of calcium oxalate in tissues can be remobil-
ized or dissolved by decreasing the synthesis and/or in-
creasing the clearance of oxalate. Remobilization is
probably a slow event that depends on, among other
factors, the accessibility of the oxalate burden to the
Fig. 3. Patient (thick line) and liver (thin line) survival after liver 6
blood stream [32]. After combined transplantation,kidney transplantation (N 5 87) [25].
plasma oxalate returns to normal before urinary oxalate
excretion does; urinary oxalate can remain elevated as
long as several weeks or months post transplantation
heart [6, 34, 35]. When orthotopic liver transplantation [4, 25]. Oxalate crystals were washed out after plasma
is considered for inborn errors of metabolism, the clinical oxalate had returned to normal; usually the remobiliza-
status of these patients at the time of transplantation tion of oxalate deposits from tissues parallels the im-
usually is better than that for other chronic hepatobiliary provement in GFR [39]. Glycolate, which is more soluble
diseases, and the survival rate of patients is 6% to 16% than oxalate and does not accumulate, is excreted in
higher than in other groups with liver failure [6]. normal amounts immediately after liver transplantation
In Europe, approximately 8 combined liver-kidney [6, 39]. In contrast to isolated renal transplantation, com-
transplantations per year have been reported in the PH1 bined liver-kidney transplantation seems able to normal-
Transplant Registry Report; the total number on file ize urinary oxalate; however, reported recurrent nephro-
between 1984 and 1997 is 87 [25]. The average age at calcinosis or renal calculi might be responsible for graft
transplantation is 17.3 6 11.7 years (range, 1.0 to 50.7 loss, as illustrated by the case report [6]. Combined trans-
years) and the average time from dialysis to transplanta- plantation should be planned when the GFR ranges be-
tion is 3.1 6 3.1 years (range, 0.0 to 14.5 years). Thirty tween 20 and 40 ml/min/1.73 m2 because at this level
prior isolated renal grafts were performed in 22 patients oxalate retention increases rapidly. Even at this late
with an actuarial graft survival rate of 40% at one year stage, damaged organs other than the kidney, such as
and 10% at five years (Fig. 2); there was definite recur- the skeleton (Fig. 4) or the heart, might benefit from
rence of oxalosis in 20 patients, and several kidneys never enzyme replacement [7, 31, 42].
functioned, including most of the remaining 10; oxalate Which of these transplant strategies is better for man-
was presumed to have been a major cause. The results aging patients who have pyridoxine-resistant PH1? Some
are encouraging, as patient survival approximates 80% authors favor isolated renal transplantation, preferably
at 5 years and 70% at 10 years (Fig. 3) [25]. In addition, from living donors after vigorous pre- and post-trans-
the renal function of surviving patients remains stable plant hemodialysis, high fluid intake, crystallization in-
over time and ranges between 40 and 60 ml/min/1.73 m2 hibitors, and diuretics; others strongly support combined
after 5 to 10 years. liver-kidney transplantation [6, 28, 43]. However, pa-
In addition, synchronous liver-kidney transplantation tients who have been treated with these two approaches
offers theoretical immunologic advantages: (1) prompt are difficult to compare, as illustrated by the difference
treatment of an acute rejection episode in one organ in median age at ESRD: 7.6 years versus 28.0 years,
might control or prevent rejection in the other [36]; (2) respectively [6]. Consequently, it is impossible to estab-
lymphocytotoxic antibodies can disappear after liver lish uniform therapeutic guidelines from these experi-
transplantation, probably because they are absorbed ences; an individualized strategy is required. The modal-
onto non-parenchymal liver cells [37]; and (3) the induc- ities and timing of transplantation must depend on the
tion of a chimerism might occur and is of particular severity of the disease and the individual risk of the
interest in inborn errors of metabolism [38]. After com- transplant procedure. One of the main difficulties is eval-
uating the individual progression of PH1; serial measure-bined transplantation, the grafted kidney can be further
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Fig. 4. Radiologic presentation of the left hip in a 17-year-old patient (A) before liver-kidney transplantation and (B) 12 months after successful
combined transplantation prior to hip replacement surgery.
ment of plasma oxalate and GFR are the most reliable The success of this procedure mainly depends on the
resumption of renal function after surgery, a processcriteria [11, 31, 39].
Early isolated renal transplantation apparently can more endangered by a combined than by a single trans-
plant procedure [32]. The primary worldwide obstaclepartially remove oxalate stores and improve the patient’s
condition without liver transplantation [26]. However, if for application of this strategy is the restricted number
of potential double organ donors for synchronous liver-we consider that graft survival is improved when renal
transplantation is performed before the onset of ad- kidney transplantation.
A few years ago, combined liver-kidney transplanta-vanced renal failure (GFR # 25 ml/min/1.73 m2), one can
question whether the half-life of the graft itself should be tion was achieved mainly in adult recipients who had
reached ESRD long before the procedure. Current expe-significantly different from that of the native kidneys.
Because the kidney is highly susceptible to oxalate rience at specialized centers has shown that the survival
of patients who underwent combined transplantation hasdamage following grafting, I believe that it is preferable
to perform isolated liver transplantation first, as long as dramatically improved. In fact, mortality and morbidity
following combined transplantation were mainly relatedrenal function is more or less preserved [32, 34]. When
isolated liver transplantation is performed in patients to the extent of systemic oxalosis. Extrarenal complica-
tions occurred less frequently in survivors with combinedwith advanced chronic renal failure, however, intercur-
rent dialysis procedures will be unable to provide a nega- transplants, whose kidney survival rate is about 95%
three years after transplantation [6]. It should also betive oxalate accretion rate despite normalization of
oxalate synthesis, and renal function can be further com- borne in mind that the quality of life of patients on long-
term dialysis or after poorly functioning isolated renalpromised by remobilized oxalate [32, 39]. Consequently,
combined liver-kidney transplantation seems to be the transplantation is usually unacceptable. Therefore, it
seems that the treatment of choice both for childrenmost reasonable procedure for the treatment of PH1
patients with advanced renal failure. In patients with and adults with pyridoxine-resistant PH1 is liver-kidney
transplantation. We speculate, however, that the youngESRD (GFR # 10 ml/min/1.73 m2), vigorous hemodialy-
sis should be started and urgent liver-kidney transplanta- age of the recipient, the absence of primary liver insuffi-
ciency, and the improved results of liver transplantationtion should be planned. In this situation, the liver graft
replaces the enzyme-deficient organ, and the renal graft will finally yield a patient survival rate at least similar
to that obtained in isolated liver transplantation for othersubstitutes for the function of the main target organ.
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metabolic diseases, with an adequate quality of life and when patients undergo transplantation early (GFR $
20–30 ml/min/1.73 m2) to limit systemic oxalosis.rehabilitation.
Isolated liver transplantation should be considered The presented strategy raises ethical problems because
it implies that a functioning liver (albeit with defectiveonly if the GFR ranges between 50 and 70 ml/min/
1.73 m2. This range allows the GFR to stabilize or im- enzyme function) be removed in a patient without he-
patic failure who does not have advanced chronic renalprove post transplantation. Arguments for such a strat-
egy include the rate of decline in GFR (10% to 20% failure. Arguments for such a course of action therefore
must rely on current knowledge of the outcome of se-decrease per year), the importance of urolithiasis (num-
ber of stones, obstruction and/or infection episodes), and verely affected patients and on long-term results of vari-
ous therapeutic options [46]. Moreover, such patients,the progression of nephrocalcinosis; this strategy con-
cerns mainly young patients with an aggressive form of who are on a waiting list for two organs, should be given
some priority because of the likelihood of rapid deterio-PH1 [34]. However, the course of the renal disease is
often unpredictable, and a sustained improvement can ration of their disease. In addition, the markedly im-
proved quality of life to be expected in transplant survi-follow a phase of rapid decrease in GFR. In this case,
the risks of hepatectomy and subsequent liver grafting vors should be given consideration, independent of that
warranted by the actuarial survival of patients and organsmust be closely evaluated, and all conservative treat-
ments must be attempted before planning organ replace- [6]. In sum, the earlier the diagnosis of PH1, the better
the chances of improving the prognosis and quality of lifement.
Several valuable adjuvant treatments exist that must in individual patients receiving aggressive conservative
treatment and pre-emptive transplantation.be adjusted to the transplant strategy. Pyridoxine admin-
istration has been proposed in patients undergoing iso-
lated renal transplantation, as this cofactor might be
QUESTIONS AND ANSWERS
effective when the enzyme defect persists (that is, when
Dr. Nicolaos E. Madias (Chief, Division of Nephrol-the patient still has a defective liver). In contrast, pyri-
ogy, New England Medical Center, Boston, Massachu-doxine administration is not justified in patients undergo-
setts, USA): Are any specific patterns of enzymatic anding enzyme replacement by liver transplantation.
clinical phenotypes associated with the mutations andFollowing all three procedures (liver, kidney, and com-
polymorphisms identified so far in patients with PH1?bined liver-kidney transplantation), the kidney must be
Dr. Cochat: Point mutations have been found in asso-protected against the damage that can be induced by
ciation with enzymatic phenotype, such as G630C andthe heavy oxalate load suddenly released from tissues.
T576A (peroxisome-to-mitochondrion AGT mistarget-Forced fluid intake (5–10 liters/1.73 m2/24 hr) supported
ing, crm1 enz1), G243A (partial mislocalization andby diuretics and the use of crystallization inhibitors (in
intraperoxisomal aggregation, crm1 enz6), G367Aview of the elevated calcium oxalate excretion in the
(normal localization but loss of catalytic activity, crm1,post-transplant period) is the most important strategy.
enz-), C682T and T735C (absence of catalytic activityMeasurement of oxalate crystal volume appears to be a
and immunoreactive protein, crm- enz-) [4]; other newlyhelpful tool in renal graft management after combined
reported mutations (T444C, G640A, G690A, 1008-1010-liver-kidney transplantation [44]. The role of daily high-
delGCG, G1171A) might have consequences on enzymeefficiency (pre- and) post-transplant hemodialysis and of
location and/or activity [47]. However, there is no furtherhemofiltration is still debated. It should be proposed on
relationship between liver AGT activity and clinical pre-the basis of a rapid drop in plasma oxalate; however, it
sentation: adult patients can experience initial symptomscan increase the risk of calcium-oxalate crystallization
at 50 years of age with 0% AGT activity, whereas infantsas shown by crystalluria assessment [44] and therefore
with 20% AGT activity can suffer from a severe formshould be limited to patients with severe bone disease. In
of the disease as early as birth [4, 48]. Hoppe et al havemost patients receiving renal transplants, native kidneys
shown a lack of relationship among genotype, enzymaticshould be removed because they are prone to frequent
phenotype, and disease severity in one family containingepisodes of infection and obstruction [45, 46].
four affected individuals in two different generations
[49]. In patients with isolated renal transplantation, the
CONCLUSION fate of the graft was unrelated to residual AGT activity
[28, 30].The European experience suggests that (1) combined
liver-kidney grafting can produce excellent results in Dr. Madias: Could you comment on the level of AGT
activity in heterozygotes? Are heterozygotes at risk?PH1 patients; (2) renal transplantation alone has little
role in the treatment of this disease; and (3) liver trans- Dr. Cochat: Heterozygotes are obligate carriers and
are asymptomatic. Their AGT activity ranges betweenplantation reverses the underlying metabolic defect and
its clinical consequences [25]. The outcome is improved 20% and 60% of mean control values, a level comparable
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to some crm1 enz- PH1 patients with significant residual Others have demonstrated in microvesicle studies a spe-
cific oxalate-transporting protein [55]. Has the possibilityenzyme activity [4, 50]. In heterozygotes, analyses of
DNA and intracellular distribution of immunoreactive of inhibiting secretor proteins with agents such as cimeti-
dine and trimethoprim been explored, and if so, whatAGT by immunoelectron microscopy are mandatory.
Dr. M. A. Lewis (Royal Manchester Children’s Hospi- was the effect on urinary oxalate levels? Also, whereas
all thiazide diuretics have a common site of action on thetal, Manchester, England): You mentioned using AGT
activity for diagnosing PH1 in patients who present with NCCT receptor in the distal convoluted tubule, different
agents have different effects on transport along the seg-what you described as clinical oxalosis or hyperoxaluria,
and I think about 14% of those had normal AGT activity, ments of the proximal tubule. Might such effects influ-
ence oxalate secretion?whereas another 16% had between 5% to 50% of the
mean normal activity. What do you think is the basis of Dr. Cochat: I am not aware of any possible effect of
cimetidine or trimethoprim on tubular oxalate secretion.hyperoxaluria in these patients?
Dr. Cochat: The percentage of our patients who were Thiazides can decrease calcium excretion, but I know of
no information on their potential influence on oxalateexcluded from the PH1 diagnosis was comparable to that
reported by Danpure and Rumsby [4]. Of course, we excretion. However, the interaction between oxalate and
tubular cell metabolism is an important issue; we havechecked these patients for PH2, but none was positive.
Van Acker et al published a very interesting report of just shown in a rabbit experimental model that the pres-
ence of oxalate itself has deleterious effects on the inter-two unrelated patients with pyridoxine-resistant hyper-
oxaluria and hyperglycoluria along with normal AGT mediary metabolism of renal tissue (Di Maio et al, un-
published data). The primary insult to the kidneyactivity and normal localization of the enzyme in the
peroxisome [51]. Their report suggests that we might be therefore should be due to both a direct effect of oxalate
on tubular cells and the presence of crystals in the inter-able to identify in the future other enzymatic deficiencies
leading to hyperoxaluria among patients who don’t have stitium with subsequent inflammatory reaction. These
two early events might play a major role in the initiationthe enzymatic hallmark of PH1. I think hyperoxaluria is
a front door, and we have a lot of rooms inside with of progressive renal damage.
Dr. Madias: Dr. Plant, did you mean that in PH1various enzymatic deficiencies that are currently hard to
identify. patients there is net tubular secretion of oxalate rather
than net reabsorption?Dr. D. O’Donoghue (Hope Hospital, Salford, En-
gland): You mentioned that cytosolic GGT can manifest Dr. Plant: I believe that in normal circumstances
there is net oxalate reabsorption. However, as one mightAGT activity in vitro and must be controlled for in the
assay. Does cytosolic GGT have any AGT activity in expect, in states with high plasma oxalate levels, there
is net secretion.vivo?
Dr. Cochat: Glutamate:glyoxylate aminotransferase Dr. O’Donoghue: Could you define pyridoxine sensi-
tivity and give us your insights into the mechanism of(GGT, EC 2.6.1.4) is responsible for cytosolic detoxifica-
tion of glyoxylate into glycine (Fig. 1), and its activity this effect? Does pyridoxine sensitivity tell us anything
about clinical heterogeneity?is normal in patients with PH1. In vitro, GGT shows
reactivity towards alanine, being about two-thirds as ac- Dr. Cochat: Indeed, there are no definite criteria to
check for pyridoxine sensitivity. Defined by the evolutiontive with alanine as it is with glutamate [14, 52]; the
AGT activity therefore should be corrected for this 65% of urinary oxalate and glycolate during pyridoxine treat-
ment, the responsiveness can be complete, partial, orcrossover from GGT. The major clinical consequences
of peroxisomal AGT deficiency demonstrate the quanti- absent [56]; only 5% to 10% of patients show a partial
or complete response following the administration oftative importance of peroxisomal transamination in the
detoxification of glyoxylate. Such a defect in PH1 proba- small to pharmacologic doses [57]. Such a response
would be influenced by the degree of residual AGT activ-bly allows peroxisomal glyoxylate to pass into the cytosol
(Fig. 1), where some glyoxylate is transaminated into ity, the dose of pyridoxine, and the stage of the disease;
pyridoxine sensitivity therefore could contribute to theglycine by cytosolic GGT, which therefore has AGT
activity [14, 53]. However, this AGT activity of cytosolic so-called “clinical phenotype.” This effect should be due
to increased glyoxylate transamination (by inducing theGGT is likely to be quantitatively limited.
Dr. W. Plant (Royal Infirmary of Edinburgh, Scot- synthesis or inhibiting the catabolism of the apoenzyme)
and to overcoming the effects of mutations in the AGXTland): Would you comment on the mechanisms of secre-
tion of oxalate in the proximal tubule? In a condition gene that might interfere with cofactor binding [58].
Dr. P. Ackrill (Withington Hospital, Manchester):such as this, any maneuver that diminishes the luminal
concentration of oxalate must be important and should May I ask about urinary oxalate excretion? I have a 37-
year-old lady with pyridoxine-sensitive PH1 who re-be pursued. I believe that some have suggested that a
number of anion secretory pathways are involved [54]. ceived a live-donor renal transplant from her mother 11
Nephrology Forum: Primary hyperoxaluria type 1 2543
years ago and has had 3 pregnancies since. Her renal 82 6 25, respectively; P 5 0.04). These data can be
applied to transplant patients in the peri-operative pe-function is normal, but her urinary oxalate levels are
increasing: previously, the oxalate was , 1.0 mmol/24 riod. In addition, continuous convective therapy is better
tolerated with respect to hemodynamics and thereforehours but now it exceeds 2.0 mmol/24 hours. She is still
taking pyridoxine. Why is the urinary oxalate excretion protects the patient against oliguria, which increases the
risk of crystalluria [44].increasing? It also rose during pregnancy; could this be
related to AGT activity or to loss of pyridoxine sensitiv- Dr. O’Donoghue: Could you give us an idea of the
postdialysis oxalate level we should aim for with inten-ity? Or is this increase part of the natural history in a
kidney-only transplant patient? sive dialysis? Is it necessary for dialytic oxalate removal
to match or exceed liver oxalate production?Dr. Cochat: If the GFR is normal, I have no clear
explanation. Bone oxalate disease, which can generate Dr. Cochat: In patients who remain on regular hemo-
dialysis, predialysis oxalate levels should stay below 40high amounts of oxalate in plasma and urine, usually is
associated with a decrease in GFR. Otherwise such an to 50 mmol/liter to limit supersaturation of body fluids,
a major factor for progression of systemic oxalosis [10].increase in urinary oxalate should be regarded as a po-
tent marker of renal allograft dysfunction. In addition, No data are available on the target postdialysis plasma
oxalate concentration. In any case, when dialysis is man-in your patient, pyridoxine responsiveness might have
changed along with time. I have no information on a datory, one should at least try to match oxalate overpro-
duction; that requires intensive daily hemodialysis, sixpotential effect of pregnancy on peroxisomal glyoxylate
metabolism. to eight hours per session [26]. After transplantation,
the dialysis strategy should be adapted to a number ofDr. I. Nyakundi Keengwe (Royal Manchester Chil-
dren’s Hospital): How can you determine the total-body variables, including the estimated size of oxalate storage,
the urine output, crystalluria, and the plasma oxalateoxalate load before liver/kidney transplantation so as to
accurately plan the time course in terms of hemodialysis level, which should be kept below 10 to 15 mmol/liter
[42, 60].duration prior to transplantation?
Dr. Cochat: This is a very important issue, since all Dr. R. Ahmad (Royal Liverpool Hospital, England):
In the late 1960s, David Kerr demonstrated oxalate de-kinds of transplants theoretically should precede ad-
vanced systemic storage and the consequent need for position in the myocardium of patients with end-stage
renal failure who were on hemodialysis. The cardiomy-dialysis. Criteria that would further predict changes in
GFR and allow early assessment of systemic storage opathy that we see in primary hyperoxaluria presumably
is due to oxalate deposition. This patient had an ejectiontherefore are needed. Sequential assessment of the GFR,
of the plasma oxalate:creatinine ratio, and possibly of fraction of 34%. Do you think that the oxalate deposition
in the myocardium would resolve following transplanta-systemic involvement, that is, bone histology, skeletal
and soft tissue radiographs, funduscopy, and dual-energy tion, and what are the risks of transplantation?
Dr. Cochat: We cannot investigate accurately oxalatex-ray absorptiometry (Behnke B, personal communica-
tion), should be performed. Assessment of oxalate meta- deposition in the myocardium, but many patients did
suffer from angina pectoris or arrhythmias prior to trans-bolic pool size and tissue oxalate accretion rate may
provide one theoretical approach. plantation. However, cardiomyopathy can improve or
reverse with combined liver-kidney transplantation, asDr. Plant: Regarding the peri-operative management
of the patient, you mentioned different renal replace- evidenced by normalization of cardiac size, a dramatic
increase in the left-ventricular ejection fraction, resolu-ment therapy approaches. Based on the molecular mass
of oxalate and its probable high volume of distribution, tion of cardiac arrhythmias, and disappearance of cardiac
uptake on bone scanning [61].it seems likely that a considerable rebound of plasma
oxalate occurs after a hemodialysis session. Does this Dr. P. A. Kalra (Hope Hospital, Salford): What about
the arterial lesions that this patient is developing? Isoccur, and if so, might a continuous convective therapy
be more appropriate in maintaining low levels after an there any evidence that they contribute to the cardiomy-
opathy? Second, what is the evidence for regression ofinitial intense hemodialysis treatment?
Dr. Cochat: You are right. Plasma profiles and dialysis these arterial lesions after transplantation?
Dr. Cochat: Some evidence comes from biopsies orkinetics of oxalate have been studied by Marangella et
al in adult patients on regular dialysis treatment for end- autopsies. In addition, our experience has shown that
calcium oxalate deposition in the arteries declines afterstage renal disease unrelated to PH1 [59]. From this
study, the estimated volume of distribution of oxalate is transplantation, as indicated by thallium scintigraphy in
patients with cardiac involvement and by thermography21.5 6 5.7 liter, that is, 37.3% 6 11.3% of dry body
weight. Indeed, there is a postdialytic oxalate rebound, in patients with limb arterial problems (unpublished
data). Many patients undergoing dialysis experience se-and dialyzer clearance of oxalate is mildly higher on
hemodiafiltration than on hemodialysis (113 6 45 versus vere problems with their arteriovenous fistulas (throm-
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boses sometimes leading to distal limb amputation), but ity, which is normal in PH2 [63]. Such cases might have
significant improvement after isolated renal transplanta-there are no available data on the outcome of vascular
accesses after transplantation. tion despite possible recurrence.
Dr. Cameron: Would they have vascular infiltrationDr. P. McClelland (Arrowe Park Hospital, Wirral,
England): Given the longevity of some patients after as he did?
Dr. Cochat: Usually not.presentation of the disease, is there currently a role for
conservative treatment rather than transplantation? Dr. Cameron: I think in fact he was studied, not by
AGT activity on a liver biopsy, but I think Richard WattsDr. Cochat: The earlier the diagnosis is made, the
more efficient conservative treatment becomes in chil- checked his glycolic and glyceric acid, and diagnosed
primary hyperoxaluria type 1.dren as well as in adults. The GFR can be preserved for
a long time with aggressive conservative treatment. The Dr. Cochat: I have another comment about your
question on the chronology of organ transplantationliterature contains several reports of children diagnosed
at birth who were started early on conservative treatment since you suggested a first-step kidney transplant fol-
lowed by a liver transplant.with very good results, that is, delayed renal death. I
have cared for two patients from two different families Dr. Cameron: I was not advocating this as an elective
course, but as a further stage of management, given thatwho were actively treated from birth; index siblings had
previously received liver or liver plus renal transplants this problem has arisen in my patient after isolated renal
transplantation.at around five years of age. Despite a complete AGT
deficiency in all, the patients who started the treatment Dr. Cochat: This option indeed can be proposed to
such patients. However, on immunologic grounds, meta-at birth had normal GFRs and height at age 10 years.
Also, Milliner et al showed that with aggressive conserva- chronous liver transplantation from another donor is
more hazardous.tive treatment, you can consistently increase the half-
life of the native kidneys [22]. This issue is of major Dr. J. Firth (Addenbrooke’s Hospital, Cambridge,
England): Combined liver-kidney transplantation is aconcern and must be particularly promoted in devel-
oping countries. major operation with the substantial risk that hemody-
namic instability will cause delayed renal allograft func-Dr. J. S. Cameron (Guy’s Hospital, London, Eng-
land): I have a question about the long-term outlook tion. Given that this procedure can lead to graft loss
from oxalate deposition, what are your views on sequen-and management of patients given isolated renal trans-
plants. I have in mind a patient of ours who, more than tial liver then kidney transplantation, since this approach
might offer a better chance of good initial renal function?10 years ago, received a successful cadaver kidney graft
that still functions well. The patient received the same Dr. Cochat: I have no personal view, but sequential
liver-kidney transplantation has been done before in atype of treatment you outline, including pyridoxine, al-
though I have to admit we used frusemide, not thiazide. few cases. The approach was not beneficial because the
recipients were strongly immunosuppressed due to priorHowever, his plasma oxalate never quite returned to
normal, and incidental surgery revealed that his medium- transplantation [22 and unpublished data]. The rate of
infection was increased because patients were submittedsized arteries were rotten with oxalate deposits. Would
you consider a late hepatic transplant under such circum- to two sequential immunosuppression courses, and the
risk of rejection was higher because two different donorsstances, and if so, on what grounds? There must be a
growing number of such patients in the United States. were used. The success of renal transplantation therefore
seemed to be compromised, but we cannot draw anyDr. Cochat: I am not sure the number of such patients
is so substantial; most patients with primary isolated conclusions from such a small number of patients.
Dr. Madias: Can you summarize for us your viewsrenal transplantation had graft failure and returned to
dialysis, ultimately to receive a combined transplant [6, on the management of PH1, depending on the age at
presentation and as it relates to developed versus devel-25, 62]. Did you check AGT activity in your patient?
Dr. Cameron: He never had a liver biopsy to assess oping nations?
Dr. Cochat: The age at initial symptoms is critical.AGT activity. He had a horseshoe kidney plus stones,
and the diagnosis was missed, although the kidney was Infantile forms are the most severe forms, since 50% of
children die during the first year of life because of techni-heavily calcified. The correct diagnosis only came to light
when he received his father’s kidney without any prepa- cal limitations of the treatment. Peritoneal dialysis, which
can be started during the first weeks of life, cannot pro-ration; the kidney was immediately destroyed by recur-
rent oxalosis. vide sufficient oxalate clearance. Combined liver-kidney
transplantation is quite hazardous during the first yearDr. Cochat: In some patients such a presentation
might be related to primary hyperoxaluria type-2 (PH2), of life and many recipients have died. In fact, the man-
agement of PH1 infants depends on the economic leveland therefore patients with a so-called “successful” iso-
lated renal transplant should be checked for AGT activ- of the country. In developed countries, we try to manage
Nephrology Forum: Primary hyperoxaluria type 1 2545
the patients until combined transplantation becomes Dr. Cochat: We have no available data about the
available, whereas in developing countries PH1 is a fre- incidence of PH2, which might represent less than 5% of
quent cause of withdrawal of therapy. the total number of primary hyperoxalurias [5]. Urinary
With respect to the overall management of this dis- oxalate itself is usually in a lower range than in PH1
ease, it remains controversial whether to embark on elec- and, instead of glycolate, one finds increased urinary
tive isolated liver transplantation or combined liver-kid- excretion of L-glycerate. Deficiency of the enzyme
ney transplantation. The course of the disease is more D-glycerate dehydrogenase, which also has glyoxylate
important than the patient’s age; some patients have reductase activity and is present mainly in the liver and
their first symptoms at two years of age, others as late leukocytes, is believed to be the underlying cause of PH2
as the third decade. Symptomatic patients can experience [64]. Although end-stage renal disease seems to develop
further rapid progression of the disease, that is, more less frequently than in PH1 patients, chronic and termi-
than a 15% to 20% decrease in GFR per year, that can be nal renal insufficiency can occur. It is therefore important
a criterion for pre-emptive, isolated liver transplantation. that we evaluate patients who have a clinical picture of
However, the final therapeutic option usually depends PH1, because it can mimic PH2.
more on the physician’s views than on the patient’s con- Dr. Madias: What are the prospects for gene therapy?
dition.
Dr. Cochat: The design of gene therapy in PH1 has
Dr. S. Hulton (Children’s Hospital, Birmingham,
been discussed by Danpure and Rumbsy in an outstand-England): I wanted to comment about the clinical course
ing review [4]. Although liver transplantation can beof the patient as being most helpful in conducting future
considered a kind of gene therapy as well as a form oftreatment. I think that this is one of the most important
enzyme replacement therapy, it is not fully satisfactory.aspects in pediatric management because you can have
A more elegant approach would be to replace only thepatients with exactly the same gene mutation who have
abnormal gene, leaving all the normal ones intact. Sev-clinical heterogeneity. It is the clinical course, I imagine,
eral arguments favor successful gene therapy: (1) PH1that largely determines the treatment options and out-
is a chronic progressive disease without CNS involve-come; some patients might require no treatment, and
ment and with reversible complications; (2) PH1 is aothers very intensive treatment.
monogenic disease and the AGXT gene is well character-Dr. Cochat: I agree with you.
ized; and (3) PH1 is a liver-specific disease and genesDr. J. Iqbal (Burnley General Hospital, Burnley, Eng-
can easily target the liver. However, there are no goodland): You mentioned prenatal diagnosis. Can you elabo-
animal models and a very high percentage of cells (atrate on that? Second, what prospects do you see for
prenatal diagnosis becoming a practical strategy avail- least 75%) must express the normal transgene, since
able in a developing world in the foreseeable future? untargeted hepatocytes will continue to synthesize high
Dr. Cochat: In families in which a point mutation has amounts of oxalate. In addition, the consequences of
been found, prenatal testing using DNA analysis can AGT overexpression and possible ectopic expression are
be done from a chorionic villus biopsy during the first unknown. Nevertheless, I believe gene therapy will be
trimester of pregnancy. This method, which uses a com- considered in the next few years.
bination of linked polymorphisms and detection of the
most common mutations, leads to a diagnostic accuracy
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